CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions		Sep. 30, 2018	Dec. 31, 2017
Assets
Cash and cash equivalents	[1]	$ 3,559	$ 1,342	[2]
Short-term investments	[1]	13,680	18,650
Trade accounts receivable, less allowance for doubtful accounts: 2018—$567; 2017—$584	[1]	10,024	8,221
Inventories	[1],[3]	8,184	7,578
Current tax assets	[1]	3,686	3,050
Other current assets	[1]	2,450	2,301
Total current assets	[1]	41,583	41,141
Long-term investments	[1]	6,444	7,015
Property, plant and equipment, less accumulated depreciation: 2018—$17,078; 2017—$16,172	[1]	14,036	13,865
Identifiable intangible assets, less accumulated amortization	[1],[4]	45,306	48,741
Goodwill	[1]	55,614	55,952
Noncurrent deferred tax assets and other noncurrent tax assets	[1]	1,875	1,855
Other noncurrent assets	[1]	2,980	3,227
Total assets	[1]	167,838	171,797
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2018—$4,255; 2017—$3,546	[1]	7,385	9,953
Trade accounts payable	[1]	4,297	4,656
Dividends payable	[1]	1,963	2,029
Income taxes payable	[1]	2,781	477
Accrued compensation and related items	[1]	2,096	2,196
Other current liabilities	[1]	10,490	11,115
Total current liabilities	[1]	29,013	30,427
Long-term debt	[1]	33,652	33,538
Pension benefit obligations, net	[1]	4,886	5,926
Postretirement benefit obligations, net	[1]	1,455	1,504
Noncurrent deferred tax liabilities	[1]	5,512	3,900
Other taxes payable	[1]	15,289	18,697
Other noncurrent liabilities	[1]	6,367	6,149
Total liabilities	[1]	96,174	100,141
Commitments and Contingencies	[1]
Preferred stock	[1]	20	21
Common stock	[1]	466	464
Additional paid-in capital	[1]	85,828	84,278
Treasury stock	[1]	(96,574)	(89,425)
Retained earnings	[1]	91,995	85,291
Accumulated other comprehensive loss	[1]	(10,417)	(9,321)
Total Pfizer Inc. shareholders’ equity	[1]	71,319	71,308
Equity attributable to noncontrolling interests	[1]	346	348
Total equity	[1]	71,664	71,656
Total liabilities and equity	[1]	$ 167,838	$ 171,797

[1] Amounts may not add due to rounding.

[2] Amounts may not add due to rounding.

[3] The change from December 31, 2017 reflects increases for certain products to meet targeted levels in the normal course of business, including inventory build for supply recovery, network strategy and new product launches, partially offset by a decrease due to foreign exchange.

[4] The decrease in Identifiable intangible assets, less accumulated amortization, is primarily due to amortization, partially offset by additions, mainly consisting of $240 million of Developed technology rights recorded in connection with the EU approval of Mylotarg (see Note 7E).